Evaluation of [18F]LU14 and [18F]LU13 in a rat model with a local overexpression of the human cannabinoid receptor 2 in the brain with PET

Objectives: An upregulation of cannabinoid receptors type 2 (CB2) has been reported in association with inflammation processes, traumatic brain injury, neurodegeneration and cancer.[1] The activation of CB2 leads to an anti-inflammatory action. Therefore, the non-invasive assessment of the CB2 availability with PET could improve the decision-making for CB2-directed therapies. We developed a series of fluorinated naphthyridine-2-one-carboxamides as CB2 ligands, of which [18F]LU14[2] and [18F]LU13 were radiosynthesized and biologically evaluated.
Methods: The two radioligands [18F]LU14[2] and [18F]LU13 were developed starting from appropriate precursor compounds.The fraction of radiometabolites was quantified in isolated plasma and brain samples at 30 min p.i. The CB2 binding affinities selectivities (expressed and determined from KD and Ki values of both radioligands were determined in vitro. PET studies were performed to evaluate the radioligand uptake into the brains of rats overexpressing the hCB2(D80N) in the right striatum[3].
Results: Favourable properties where achieved for [18F]LU14, which could be further improved for [18F]LU13 (AM, affinity, selectivity and metabolic stability). In rats bearing the local overexpression of the hCB2 a target-specific and reversible uptake for both radioligands was demonstrated. [18F]LU14 reached a TAC peak SUV of 3.3 ± 0.6 at 7.4 ± 2.8 min p.i., and the SUVr (target region–to–cerebellum) was stable between 6.6 and 7.0 after 30 min p.i. For [18F]LU13 a stable SUV of 3.6 ± 0.9 after 26 min p.i. was reached and a close to linearly increasing SUVr (target region–to–cerebellum) up to 8.8 ± 4.3 at 60 min p.i. was determined (slope = 0.15 SUV/min; R² =.0.8).
Conclusion: [18F]LU14 and [18F]LU13 showed an excellent ability to image the CB2 receptors in vivo. Additionally, [18F]LU14 revealed a faster washout from the non-target regions in the brain, compared to [18F]LU13.
References: [1] Stasiulewicz et al. IJMS, 2020, 21, 2778; [2] Teodoro et al. IJMS, 2021, 22, 15; [3] Attili et al. BJP, 2019, 176, 1481